In 2021, a comprehensive national serosurvey in Ukraine provided critical insights into the epidemiology of viral hepatitis within the country, revealing a weighted prevalence of 3.3% for hepatitis C virus (HCV) antibodies, 11.6% for hepatitis B core antibodies (anti-HBc), and .9% for hepatitis B surface antigen (HBsAg), an indicator of active hepatitis B virus (HBV) infection. Notably, among individuals testing positive for HBsAg, 7.5% also demonstrated antibodies against hepatitis D virus (HDV), highlighting the presence of this less common but clinically significant coinfection that exacerbates liver disease progression.1
The study results were derived from blood samples collected during a household-based SARS-CoV-2 serosurvey, with testing for hepatitis B, C, and D markers. Post-stratification weighting adjusted for Ukraine’s population distribution by sex, age, and urbanization, with additional regional prevalence estimates generated. Prevalence of hepatitis B and C markers was notably higher among men and residents of southern Ukraine, indicating widespread past or current exposure to these viruses.1
The investigators note, “This nationwide study provides the first representative estimates of viral hepatitis markers across Ukraine, highlighting significant regional and demographic disparities. Our findings underscore the critical need to enhance vaccination programs and implement targeted interventions to mitigate the burden of hepatitis B, C, and D nationwide.”1
Several limitations affect interpretation: the survey was designed for SARS-CoV-2 antibodies and lacked hepatitis risk factor data, limiting risk assessment; sample size assumptions may reduce precision for low-prevalence infections; demographic differences required weighting for representativeness; exclusion of COVID-19-vaccinated individuals could affect generalizability; active HCV infection couldn’t be assessed due to missing RNA/antigen testing; HBsAg testing only in anti-HBc-positive participants may underestimate HBV and HDV prevalence; and regional sample sizes were too small for detailed analysis. Despite these issues, the study offers valuable baseline data to guide Ukraine’s hepatitis control amid ongoing challenges.1